Spike Health adds a health food grape seed extract soft capsule to obtain re-registration approval
Release time:
2020-07-15
Recently, Jianfeng Health Technology Company has obtained the registration approval certificate of "Jianfeng Renshou Hall Grape Skin Agaricus blazei Murrill Capsule", and the re-registration of Sunemei Grape Seed Extract Soft Capsule has been approved by the State Drug Administration.
grape skin agaricus blazei capsule is grape skin, agaricus blazei, pine pollen extract as the main raw material made of health food. According to relevant literature records, grape skin contains resveratrol polyphenols. Resveratrol has multiple functions, which can promote the differentiation of early and young cells, improve the conversion rate of lymphocytes, and enhance the body's immunity; pine pollen is the dried pollen of the pine family. Agaricus blazei is a kind of basidiomycete used for both food and medicine. The fruit bodies of pine pollen and Agaricus blazei are are rich in polysaccharides and have biological active substances. The three are safe raw materials, and there is no incompatibility, and they are used in conjunction with each other. After evaluation by animal experiments, they have the health care function of enhancing immunity.
grape skin Agaricus blazei Murrill capsule, suitable for people with low immunity, can alleviate the symptoms caused by low immunity, such as weakness, dizziness, palpitations, shortness of breath, insomnia and forgetfulness, enhance human immunity, will have good development space and economic benefits. Since the soft capsule extracted from
Sunimei brand grape seed has been on the market, it has been widely concerned by the market and favored by consumers with the advantages of grape seed extract industry standard setter, patent for extraction of proanthocyanidin B2 and medicinal patents for related diseases such as proanthocyanidin B2 diabetes, selection of raw materials, high content of active ingredients, modern low-temperature extraction and other processes and technologies.
The original approval document of Sunemi was obtained in 2011. According to the new "Administrative Measures for Registration and Filing of Health Food", an application for renewal was submitted in 2016. Due to the adjustment of the competent department and the delay in approval, Jianfeng Health received the approval document for re-registration in the near future. During the re-registration application approval period, the original approval document continues to be valid. During the re-registration period, Jianfeng Health summarized and analyzed the production and sales of Shinimei, the consumption of the population, and the operation of the production quality management system, revised the instructions, and upgraded the product quality standards. (wang siqi and yang hao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page